Based on clinical trial results, there is an increasing evidence that CAR-T cells have the ability to deliver powerful anti-tumor therapeutic effects, leading to the recent FDA approval of CAR-T therapies directed against the CD19 protein for the treatment of acute lymphoblastic leukemia (ALL) and large B-cell lymphoma (DLBCL). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.